Suda Pharmaceuticals Ltd. has appointed Dr. Debora Barton, MD, as an independent Non-Executive Director. Dr. Barton has over 20 years' experience in the field of oncology. After practicing oncology as a physician and clinical trial investigator, she spent five years at Novartis and five years at Celgene in roles of increasing responsibilities in Medical Affairs and Clinical Development. Dr. Barton has extensive experience working with cell therapy products, formerly as the Senior Vice President, Clinical and Head of Safety, of the clinical stage company, Iovance, who are developing T cell therapies for cancer treatment. Dr. Barton is currently the Chief Medical Officer of Carisma Therapeutics, a clinical stage biopharmaceutical company, developing innovative immunotherapies including the first in class chimeric antigen receptor (CAR) macrophages for the treatment of certain cancers.